Theraxen harnesses the power of xeno-nucleic acids to unlock transformative therapeutic solutions for diseases that demand innovation.
At Theraxen, we believe that the next generation of therapeutics lies beyond the boundaries of natural nucleic acids. We design, develop, and deploy xeno-nucleic acids—synthetic alternatives to DNA and RNA—that offer unprecedented stability, specificity, and therapeutic potential. Our proprietary platforms enable the creation of novel molecular medicines that address a broad spectrum of human diseases.
Xeno-nucleic acids represent a paradigm shift in molecular therapeutics. By reimagining the chemistry of nucleic acids, we create molecules with enhanced pharmacokinetic properties, improved target recognition, and reduced immunogenicity. This breakthrough approach opens new therapeutic windows and enables treatments previously thought impossible.
Superior resistance to nuclease degradation, enabling prolonged therapeutic activity with reduced dosing requirements.
Unmatched specificity in recognizing and modulating disease-relevant molecular targets across diverse therapeutic areas.
Applicability across oncology, genetic diseases, infectious diseases, neurodegeneration, and beyond—wherever molecular precision is needed.
Engineered designs that minimize off-target immune activation, improving tolerability and safety profiles.